Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023
SKU ID : TNV-14462837 | Publishing Date : 11-Jul-2019 | No. of pages : 121
Detailed TOC of Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
Market segmentation by application
Comparison by application
Attention-deficit hyperactivity disorder - Market size and forecast
2018-2023
Narcolepsy - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by application
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
R&D of stimulants to treat attention-deficit hyperactivity disorder
Rising demand to legalize cannabis worldwide
Increasing repurposing of drugs
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
GlaxoSmithKline Plc
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global central nervous system (CNS) disorders drugs market
Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Product overview
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Attention-deficit hyperactivity disorder - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Attention-deficit hyperactivity disorder - Year-over-year growth 2019-2023 (%)
Exhibit 22: Narcolepsy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Narcolepsy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: GlaxoSmithKline Plc - Vendor overview
Exhibit 47: GlaxoSmithKline Plc - Business segments
Exhibit 48: GlaxoSmithKline Plc - Organizational developments
Exhibit 49: GlaxoSmithKline Plc - Geographic focus
Exhibit 50: GlaxoSmithKline Plc - Segment focus
Exhibit 51: GlaxoSmithKline Plc - Key offerings
Exhibit 52: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 53: Johnson & Johnson Services Inc. - Business segments
Exhibit 54: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 55: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 56: Johnson & Johnson Services Inc. - Segment focus
Exhibit 57: Johnson & Johnson Services Inc. - Key offerings
Exhibit 58: Novartis AG - Vendor overview
Exhibit 59: Novartis AG - Business segments
Exhibit 60: Novartis AG - Organizational developments
Exhibit 61: Novartis AG - Geographic focus
Exhibit 62: Novartis AG - Segment focus
Exhibit 63: Novartis AG - Key offerings
Exhibit 64: Pfizer Inc. - Vendor overview
Exhibit 65: Pfizer Inc. - Business segments
Exhibit 66: Pfizer Inc. - Organizational developments
Exhibit 67: Pfizer Inc. - Geographic focus
Exhibit 68: Pfizer Inc. - Segment focus
Exhibit 69: Pfizer Inc. - Key offerings
Exhibit 70: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 71: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 72: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 73: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 74: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 75: Validation techniques employed for market sizing
Exhibit 76: Definition of market positioning of vendors